As Gilead’s HIV, HCV Hull Leaks In Q4, Veklury Plugs Holes
No Signs Of Variant Strain Resistance To Remdesivir
Sales of COVID-19 drug Veklury helped keep sales in the black as the pandemic and generic competition weighed on HIV and HCV products; Gilead raised full-year 2021 guidance.
